131 related articles for article (PubMed ID: 27749411)
1. Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy.
Bode A; Rahbar K; Konnert J; Bögemann M; Stegger L
Clin Nucl Med; 2016 Dec; 41(12):951-952. PubMed ID: 27749411
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic value of additional
Bräuer A; Rahbar K; Konnert J; Bögemann M; Stegger L
Nuklearmedizin; 2017 Feb; 56(1):14-22. PubMed ID: 28074210
[TBL] [Abstract][Full Text] [Related]
3. 223Ra-Dichloride Response Evaluation Using 18F-Fluciclovine PET/CT and Bone Scintigraphy in a Patient With Castration-Resistant Metastatic Prostate Cancer.
Wang J; Kuker R; Serafini A
Clin Nucl Med; 2020 Nov; 45(11):e486-e488. PubMed ID: 32657864
[TBL] [Abstract][Full Text] [Related]
4. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
[TBL] [Abstract][Full Text] [Related]
5.
Sathekge M; Bruchertseifer F; Knoesen O; Reyneke F; Lawal I; Lengana T; Davis C; Mahapane J; Corbett C; Vorster M; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):129-138. PubMed ID: 30232539
[TBL] [Abstract][Full Text] [Related]
6. Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy.
Santo G; Di Santo G; Zelger B; Virgolini I
Nuklearmedizin; 2024 Jun; 63(3):219-220. PubMed ID: 38190993
[No Abstract] [Full Text] [Related]
7. 68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer.
Ahmadzadehfar H; Schlenkhoff CD; Rogenhofer S; Yordanova A; Essler M
Clin Nucl Med; 2016 Sep; 41(9):695-6. PubMed ID: 27405025
[TBL] [Abstract][Full Text] [Related]
8. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
9. Subacute Cortical Infarct Showing Uptake on 68Ga-PSMA PET/CT.
Chan M; Hsiao E
Clin Nucl Med; 2017 Feb; 42(2):110-111. PubMed ID: 27997426
[TBL] [Abstract][Full Text] [Related]
10.
Ahmadzadehfar H; Azgomi K; Hauser S; Wei X; Yordanova A; Gaertner FC; Kürpig S; Strunk H; Essler M
J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
[TBL] [Abstract][Full Text] [Related]
11. The potential of
Murray I; Chittenden SJ; Denis-Bacelar AM; Hindorf C; Parker CC; Chua S; Flux GD
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1832-1844. PubMed ID: 28612079
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
13. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
Kwee SA; Lim J; Coel MN
Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
[TBL] [Abstract][Full Text] [Related]
14. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.
Bal C; Yadav MP; Ballal S
Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
16. 68Ga-PSMA PET/CT Revealing Unusual Inguinal Canal and Distant Nodal Metastasis in a Case of Castration-Resistant Prostate Cancer.
Vadi SK; Kumar R; Mittal BR; Singh H; Singh SK
Clin Nucl Med; 2018 Apr; 43(4):279-281. PubMed ID: 29465494
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of
Bosch D; van der Velden KJM; Oving IM; Wyndaele DNJ; Weijs LE; van Schelven WD; Oyen WJG; Te Beek ET; van de Luijtgaarden ACM; Somford DM; Nagarajah J; Hermsen R; Mehra N; Gerritsen WR; van der Doelen MJ; van Oort IM
J Nucl Med; 2024 Apr; 65(4):541-547. PubMed ID: 38423781
[TBL] [Abstract][Full Text] [Related]
19. Serous Cystadenoma of the Pancreas Showing Uptake on 68Ga PSMA PET/CT.
Chan M; Schembri GP; Hsiao E
Clin Nucl Med; 2017 Jan; 42(1):56-57. PubMed ID: 27764044
[TBL] [Abstract][Full Text] [Related]
20. Biphasic ⁶⁸Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma.
Sahlmann CO; Meller B; Bouter C; Ritter CO; Ströbel P; Lotz J; Trojan L; Meller J; Hijazi S
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):898-905. PubMed ID: 26563122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
